Gastric Acid Production, Pancreatic Secretions and Blood Levels of Higher Alcohols in Patients with Fungal-type Dysbiosis of the Gut
J. Nutr. & Env. Medicine. 2002; 12(2): 107-112
Eaton K.K., Gaier H.C., Howard M., McLaren-Howard J and Reid L
Purpose: Patients with gut dysbioses are clinically difficult to distinguish from those with food intolerance. The variety known as fungal-type is associated with the generation of small amounts of ethanol in the blood. A recent study has shown abnormalities of histidine metabolism. In view of this, gastric function was studied. This also provided data on pancreatic function.
Design: Two groups of newly referred patients, with similar symptom profiles, attending two clinicians were studied. Group A (42 patients) had positive ethanol fermentation tests: group B (37 patients) did not. There were 20 healthy control subjects. Levels of higher alcohols, short-chain fatty acids, gastric acid production and pancreatic exocrine secretions were measured and compared statistically.
Materials and Methods: Ehtanol, higher alcohols and short-chain fatty acids were measured by gas-liquid chromatography. Gastric acid production, emptying time and pancreatic function were measured using a swallowed transponder.
Results: A significant number of group A patients had elevated levels of higher alcohols; all of these also showed excess short-chain fatty acids. Group B patients showed similar findings for both; these figures were not statistically significant. However, as compared with group B, group A patients were less likely to show lower levels of gastric acid and/or pancreatic enzyme production and these results were statistically highly significant.
Conclusions: As these findings show minimal effects on stomach and duodenum, it is suggested that fungal-type dysbiosis is largely an ileal condition. For these patients, the presence of elevated levels of higher alcohols with a positive ethanol test is a better indicator of disease severity.
NOTICE : Biolab Limited has gone into administration
14th July 2022
Biolab Limited has gone into administration due to the delay by The Care Quality Commission in processing our application to transfer our business activities to our laboratory site in West London following an earlier temporary suspension.
We always remained highly confident that Biolab would reopen and invested heavily in relocating the business, retaining and retraining our employees, developing new and improved methods of work and updating our documentation, so this comes as a huge disappointment for us all, but as you’ll appreciate no business can continue indefinitely without an income.
We are no longer able to process any samples for testing.
Biolab is very proud of the help we have given to hundreds of thousands of patients over 37 years, and we thank everyone for their phenomenal support and loyalty over the years, and for the hundreds of messages of support we have received in recent months.